MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-11-2026
SCYNEXIS EV - Enterprise Value 2011-2026 | SCYX
Annual EV - Enterprise Value SCYNEXIS
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.3 M | 56.4 M | 91.7 M | 117 M | 103 M | 66.1 M | 53 M | 42.1 M | 62.2 M | 46.5 M | 15.9 M | 35 M | 19.7 M | 29.1 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 117 M | 15.9 M | 54.6 M |
EV - Enterprise Value of other stocks in the Drug manufacturers industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-3.12 M | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
126 M | $ 5.6 | -1.23 % | $ 83.2 M | USA |
 |
HEXO Corp.
HEXO
|
560 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-974 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
6.79 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-11 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
-1.35 M | $ 2.68 | -2.55 % | $ 1.03 B | Canada |
 |
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
2.21 B | $ 37.64 | -0.03 % | $ 1.38 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | USA |
 |
Canopy Growth Corporation
CGC
|
459 M | $ 1.0 | -0.99 % | $ 108 M | Canada |
 |
Organogenesis Holdings
ORGO
|
408 M | $ 2.34 | -1.68 % | $ 297 M | USA |
 |
Pacira BioSciences
PCRX
|
1.68 B | $ 22.99 | -1.58 % | $ 1.06 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 1.09 | -0.91 % | $ 1.35 M | USA |
 |
Aurora Cannabis
ACB
|
330 M | $ 3.04 | -1.3 % | $ 167 M | Canada |
 |
Solid Biosciences
SLDB
|
616 M | $ 7.14 | -1.11 % | $ 625 M | USA |
 |
Jupiter Wellness
JUPW
|
3.7 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
671 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
146 M | $ 1.06 | -1.85 % | $ 101 M | Canada |
 |
Tilray
TLRY
|
1.96 B | $ 4.98 | -2.73 % | $ 3.08 B | Canada |
 |
cbdMD
YCBD
|
4.51 M | $ 0.69 | -1.72 % | $ 2.78 M | USA |
 |
Evolus
EOLS
|
467 M | $ 6.73 | 3.38 % | $ 434 M | USA |
 |
Sundial Growers
SNDL
|
-17.5 M | $ 1.42 | -2.74 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
1.04 B | $ 8.32 | -0.83 % | $ 445 M | USA |
 |
Veru
VERU
|
80.7 M | $ 3.0 | -7.98 % | $ 43.9 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-80.1 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
238 M | $ 23.48 | 0.04 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
56.3 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
715 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
26.7 B | $ 5.06 | -1.94 % | $ 1.88 B | Canada |
 |
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
251 M | $ 6.65 | 1.99 % | $ 263 M | USA |
 |
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
84.7 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
75 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
21.2 B | $ 16.48 | 1.04 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
2.62 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
43.3 M | $ 0.62 | 0.35 % | $ 22.3 M | USA |
 |
Tricida
TCDA
|
555 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
10.7 M | $ 0.71 | -6.82 % | $ 3.05 M |  China |
 |
TherapeuticsMD
TXMD
|
26.3 M | $ 2.2 | 20.88 % | $ 25.5 M | USA |